Catabasis Pharmaceuticals Inc (NASDAQ:CATB) recently announced publication of much talked about phase 1 data on edasalonexent, a treatment meant for the adults’ rare disease’s characteristic muscular degeneration. Primarily, the company said that their drug fetched positive result in the clinical study and that; the Edasalonexent was not just well tolerated, but also safe. This indicated a positive biomarker among adult patients.
Meanwhile, the company also announced that the Top-Line phase 2 results in male population with the duchenne muscular dystrophy are on track. These results may be announced in the first half of Q1 2017.
Edasalonexent is company’s indigenous drug and works on the inhibition of NF-kB pathway. This pathway is said to play a vital role in rare disease’s characteristic muscular degeneration, also known as DMD.
The positive side of this drug is that it can be used for the treatment of all kind of patients. There has been an earlier treatment for DMD by Sarepta, but it is only targeted for the patients who have a certain kind of gene mutation.
Moving ahead in an alliance, Catabasis Pharmaceuticals also has a partnership or joint alliance with Sarepta for the research and development of a plausible and effective treatment for rare disease’s characteristic muscular degeneration.
Positive results of clinical study send the Catabasis Pharmaceuticals’ shares up the pedestal
The announcement of positive results of its clinical research fetched positivity in the stock market as well. Yesterday, company’s shares went on a flight and surged 17.1% during the pre-market trade. Over the past quarter, the company’s shares have fallen 12.6%.
So, a jump in the stock after three months isn’t a bad thing. In fact, it is indicating a good start for the New Year for Catabasis Pharmaceuticals. The company now hopes to produce positive results for the clinical research of Top-Line phase 2 results in male population with the duchenne muscular dystrophy. There is a light of hope that the coming few months would be good for this company.